Navigation Links
The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
Date:11/26/2007

ern Time on November 26, 2007. A replay call will be available through December 10, 2007 by dialing 877-519-4471 (international callers dial 973-341-3080) and entering the conference code 9473190.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. World-wide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's web site at h
'/>"/>

SOURCE The Female Health Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
9. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 According ... “Global Orthobiologics Market” the global orthobiologics market was valued at ... a market worth USD 5,519.9million in 2019at a CAGR of ... population aged 50 years and above is afflicted by bone ... double by the year 2020. This has and will continue ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... BioPharma Corp.,(TSX: HBP / Frankfurt: WKN 918864), Helix ... has,increased the authorized number of directors from six to ... to fill the newly created,position. Mr. Hodgson will also ... Mr. Jack Kay who previously held the position., ...
... Disease Receive,Pharmacotherapy Within a Year of Their Diagnosis, According to a ... ... 2008 Decision Resources, one,of the world,s leading research and advisory ... marketed,as Astellas,s Harnal in Japan, is the physician,s drug of choice ...
... VIENNA, April 7 Vela Laboratories announced today ... analytical and quality control,laboratories. "Good Manufacturing Practice" is ... EU and US drug agencies. GMP compliance,ensures that ... and quality-controlled according to state-of-the-art standards., "GMP ...
Cached Biology Technology:More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy 2More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy 3Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories 2
(Date:8/28/2014)... The Entomological Society of America (ESA) is pleased to ... Honorary Member of the Society. Honorary Membership acknowledges those ... through significant involvement in the affairs of the Society ... honor are selected by the ESA Governing Board and ... will be honored at the Awards Ceremony at Entomology ...
(Date:8/28/2014)... in German . ... name to a striking pattern of blue stripes alternating with ... silvery cells, and yellow cells emerge during growth in the ... multilayered mosaic to compose the characteristic colour pattern. ... to interact to form proper stripes, the embryonic origin of ...
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3New tool aids stem cell engineering for medical research 2
... meeting of the European Society of Human Reproduction and ... which only one child is born from a pregnancy ... to a nearly two-fold increased risk in any congenital ... malformations. Prof Davies, who is an Associate Professor ...
... meeting of the European Society of Human Reproduction and ... embryo) with an incorrect number of chromosomes (known as ... genetic normalisation" so that by day five, when it ... euploid, with the correct number of chromosomes. The ...
... This meant that the calendar method predicted ovulation correctly ... Digital Ovulation test (20 test pack) predicted correctly in ... Jayne Ellis, Director of Scientific and Medical Affairs at ... the test, explained that it consisted of a digital ...
Cached Biology News:'Vanishing twin' explains increased risk of birth defects 2'Vanishing twin' explains increased risk of birth defects 3'Vanishing twin' explains increased risk of birth defects 4Early embryos can correct genetic abnormalities during development 2Early embryos can correct genetic abnormalities during development 3Early embryos can correct genetic abnormalities during development 4Simple test gives accurate prediction of ovulation to help women become pregnant 2
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
... Mouse monoclonal [HDAC8-48] to HDAC8 ... by several mechanisms such as DNA ... translational modifications of histones, which include ... epsilon-amino groups of lysine residues present ...
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: